PHARMACY

Waiting period for Bristol-ZymoGenetics deal expires

BY Alaric DeArment

NEW YORK The Hart-Scott-Rodino waiting period for Bristol-Myers Squibb’s acquisition of Seattle-based biotech company ZymoGenetics has expired, enabling Bristol’s acquisition to go through, the drug maker said Tuesday.

 

The drug maker announced the deal to acquire ZymoGenetics for $885 million, or $9.75 per share, earlier this month.

 

 

The buyout gives Bristol ownership of Recothrom, a drug used to control bleeding during surgical procedures; an investigative treatment for hepatitis C called pegylated-interferon lambda; and an investigative treatment for melanoma called interleukin-21, or IL-21.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Hi-Tech Pharmacal to market generic Subutex

BY Alaric DeArment

AMITYVILLE, N.Y. Hi-Tech Pharmacal will market a generic version of a drug used to treat opioid dependence, the company said Monday.

 

Hi-Tech announced that it would market buprenorphine hydrochloride in the 2-mg and 8-mg strengths through its Midlothian Labs division. The drug is in the form of a tablet placed under the tongue.

 

 

The tablets are a generic version of Reckitt Benckiser’s Subutex, which had sales of $75 million during the 12-month period ended in June, according to IMS Health.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES